Skip to main content
 

Latest News

Seres Therapeutics Announces Closing of Initial Public Offering

July 1, 2015
More

Diversity by Design

Seres Therapeutics has built a proprietary discovery and design platform that enables us to understand the dysbiosis associated with specific diseases.

More

Product Pipeline

SER-109, our lead development candidate for the prevention of Clostridium difficile infection, has been designated by the FDA as a Breakthrough Therapy.

More

Clinical Trials

The ECOSPORTM Phase 2 clinical study is focused on the safety and efficacy of our Ecobiotic® drug, SER-109, an investigational microbiome therapeutic orally delivered as a capsule.

More

Back to top